Dysgerminoma - Treatment

Dysgerminoma is the most common malignant ovarian germ cell tumor (~30-40% of all germ cell malignancies), occurring predominantly in women aged 10-30 years. It is the ovarian counterpart of testicular seminoma and shares its excellent chemosensitivity.

Management Algorithm

1. Surgery

Surgery is the primary treatment and serves two purposes: resection and staging.

Minimum Operation

Unilateral oophorectomy (or salpingo-oophorectomy) - fertility-sparing surgery is the standard because the tumor primarily affects young women.
The contralateral ovary, fallopian tube, and uterus should be preserved even in the presence of metastatic disease, given the excellent chemosensitivity.

Staging Procedure

A careful surgical staging should include:

Inspection and palpation of all peritoneal surfaces
Biopsy of any suspicious lesions
Unilateral pelvic lymphadenectomy + para-aortic node sampling (para-aortic spread to the renal vessel level is characteristic)
Inspection of the contralateral ovary - dysgerminoma is the only germ cell tumor with significant bilateral rates (10-15%)

Special Considerations

Gonadal dysgenesis / Y chromosome: Both gonads must be removed (>50% risk of malignancy in gonadoblastomas left in situ), but the uterus can be preserved for future embryo transfer.
Bulky resectable disease (e.g., omental cake): Cytoreductive resection is reasonable even if of unproven survival benefit.

2. Stage I Disease - Observation vs. Adjuvant Therapy

About 65% of dysgerminomas are Stage I at diagnosis.

Situation	Approach
Stage I, fully staged, no adverse features	Observation (physical exam q2 months × 12 months; CT at 6 and 12 months)
Stage I, surgical staging NOT performed	Close surveillance with CT/US pelvis+abdomen q2mo × 6mo, q3mo × 6mo, q6mo × year 2 - then BEP if relapse
Capsular rupture or higher stage	Adjuvant chemotherapy
Small contralateral ovarian focus	Resect with ovarian preservation, then BEP ×4

Stage I dysgerminoma does not require adjuvant chemotherapy when properly staged and there are no adverse features.

3. Chemotherapy

Platinum-based chemotherapy is the treatment of choice for metastatic or high-risk disease, with the major advantage of preserving fertility (unlike radiation).

Standard Regimen: BEP

Drug	Dose/Schedule
Bleomycin	30,000 IU on days 1, 8, 15 every 3 weeks
Etoposide	100 mg/m²/day × 5 days every 3 weeks
Cisplatin	20 mg/m²/day × 5 days (or 100 mg/m²/day × 1 day) every 3 weeks

Stage I (occult metastases): BEP × 3-4 cycles
Advanced disease (Stages III-IV): BEP × 4-6 cycles

Outcomes with BEP

20 evaluable patients with Stages III-IV dysgerminoma treated in GOG protocols: 19/20 alive and disease-free at 6-68 months follow-up. This confirms that even advanced-stage, incompletely resected dysgerminoma has an excellent prognosis with EP-based chemotherapy.

Alternative Regimens

EP (etoposide + cisplatin) - used when bleomycin toxicity is a concern
EC (etoposide + carboplatin) - alternative, used in select settings
VBP (vinblastine, bleomycin, cisplatin) - older regimen, rarely used now
VAC (vincristine, actinomycin D, cyclophosphamide) - historical; VAC consolidation after BEP is no longer used

4. Radiation Therapy

Dysgerminomas are exquisitely radiation-sensitive (doses of 2,500-3,500 cGy can cure even gross metastatic disease).
However, radiation almost always causes permanent infertility and is rarely used as first-line treatment in the modern era.
BEP chemotherapy is at least as effective without the fertility cost.
Radiation may still be considered in recurrent/refractory disease after chemotherapy failure.

5. Tumor Markers

Monitor throughout treatment and follow-up:

LDH - most useful marker for pure dysgerminoma
beta-hCG - elevated when syncytiotrophoblastic giant cells are present (~10-15% of cases)
AFP - should be normal in pure dysgerminoma; elevation suggests mixed germ cell tumor (EST component), which changes management
CA-125 - less specific

6. Recurrent Disease

Recurrence after surgery alone responds well to BEP
Recurrence after BEP: use salvage regimens (TIP - paclitaxel/ifosfamide/cisplatin, or high-dose chemotherapy with stem cell rescue)
Second-look surgery: its role is uncertain (?second-look noted in advanced disease, but not standard)

7. Prognosis

Stage	5-Year Survival
Stage I	>95%
Stage II-III	85-95% with BEP
Stage IV	~75-85% with BEP

Overall, dysgerminoma has the best prognosis of all malignant ovarian germ cell tumors, and even advanced disease is potentially curable.

Sources:

Berek & Novak's Gynecology, pp. 2381-2387
Harrison's Principles of Internal Medicine, 22E, p. 2171

Recent Literature Note: A 2026 systematic review (PMID 41317609) addresses post-treatment hormone replacement therapy and fertility preservation in Swyer syndrome with dysgerminoma - relevant for the subset of patients with gonadal dysgenesis requiring bilateral gonadectomy.

This is a shared conversation. Sign in to Orris to start your own chat.